Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc.

12.50
EUR
-0.50
(-3.85%)
-0.62EPS
1.66BMarket Cap
Nov 05Next Earn

Latest Stock Split

Sep 26, 2013

1:100

For every 100 shares held, investors received 1.

The split itself did not change the total investment value.

Use this split data in your app

Build with our data

Stock Split History

  1. Sep 26, 2013
    Before—
    Split ratio1:100
    After—
    Reverse
  2. Apr 06, 2010
    Before—
    Split ratio24:1
    After—
    Forward

About Iovance Biotherapeutics, Inc. stock splits

Iovance Biotherapeutics, Inc. (GETTEX:2LB) operates in the Biotechnology industry.

Iovance Biotherapeutics, Inc. company overview

When did Iovance Biotherapeutics, Inc. stock split?

Iovance Biotherapeutics, Inc.'s most recent stock split was on September 26, 2013. It was a 1-for-100 reverse split, so shareholders received 1 share for every 100 they held.

What is Iovance Biotherapeutics, Inc.'s stock split history?

Iovance Biotherapeutics, Inc. (GETTEX:2LB) has split its stock 2 times: a 24-for-1 split on April 6, 2010 and a 1-for-100 reverse split on September 26, 2013.

How many times has Iovance Biotherapeutics, Inc. stock split?

Iovance Biotherapeutics, Inc. has split its stock 2 times. This history records 2 splits between April 6, 2010 and September 26, 2013.

What is a reverse stock split?

A reverse stock split combines several shares into one and raises the price per share by the same factor, so the total value of a holding does not change. In Iovance Biotherapeutics, Inc.'s 1-for-100 reverse split on September 26, 2013, every 100 shares became one share. Companies often use reverse splits to lift a low share price, for example to keep meeting an exchange's minimum price requirement.

Will Iovance Biotherapeutics, Inc. split its stock again?

Iovance Biotherapeutics, Inc. has not announced a new split in our records. Its most recent split was on September 26, 2013, 13 years ago. Companies announce splits in advance, and any new GETTEX:2LB split will appear on this page.